Impact Biomedical Inc. (NYSE: IBO) announced that Zoar Limited filed a Form F-4 registration statement with the U.S. Securities and Exchange Commission on Sept. 10, 2026, in connection with a proposed business combination between Impact Biomedical and Zoar Ltd., formerly known as Dr. Ashley's Limited.

The registration statement includes Impact's preliminary proxy statement and is available on the SEC's website under the name "Zoar Limited." A definitive proxy statement will be mailed to Impact stockholders once the registration statement is declared effective by the SEC.

Completion of the business combination is subject to several conditions, including the SEC declaring the registration statement effective, approval by Impact stockholders, approval of the listing of Zoar Limited shares on NYSE American, and satisfaction or waiver of other conditions outlined in the merger and share exchange agreement.

If approved and closed, the merged entity is expected to operate as a pharmaceutical company focused on the development and supply of active pharmaceutical ingredients and intermediates for specialty therapeutic treatment areas.

Zoar Ltd. describes itself as a global pharmaceutical company involved in the development and manufacturing of active pharmaceutical ingredients, formulations, orphan drugs, and contract development and manufacturing services. Impact Biomedical focuses on biopharmaceutical and consumer healthcare technologies developed through licensing, co-development, and joint ventures.